Risk factors associated with pseudoaldosteronism in patients with chronic hepatitis: A retrospective cohort study

Basic Clin Pharmacol Toxicol. 2019 May;124(5):607-614. doi: 10.1111/bcpt.13178. Epub 2018 Dec 18.

Abstract

Glycyrrhizin is used to treat chronic hepatitis, but it also plays an important role in pseudoaldosteronism. Multidrug resistance-associated protein 2 is important for glycyrrhizin excretion. Dysfunction of this transporter increases the serum levels of direct bilirubin, glycyrrhizin and its metabolites. Hence, elevated direct-bilirubin levels could predict the risk of pseudoaldosteronism. This study aimed to evaluate the relationship between elevated direct-bilirubin levels and hypokalaemia, which is the most sensitive marker of pseudoaldosteronism. This retrospective cohort study was conducted in a Japanese university hospital. The occurrence of hypokalaemia is defined as a serum potassium level of ≤3.5 mEq/L after the administration of a glycyrrhizin-containing medication, and a further decline of ≥0.5 mEq/L or an increase of ≥0.5 mEq/L after discontinuing the glycyrrhizin-containing medication was examined in patients with chronic hepatitis between January 2009 and December 2015. This analysis involved 1392 patients, including 596 women. Hepatitis C virus infections were the most common cause of chronic hepatitis in this study. Seventy-nine patients received glycyrrhizin (exposed group; mean age: 60.5 ± 14.2) and 1313 did not receive glycyrrhizin (control group; mean age: 58.3 ± 15.8 years). Synergistic effects of glycyrrhizin-containing medications and elevated direct-bilirubin levels were associated with hypokalaemia. Elevated direct-bilirubin levels and hypoalbuminaemia were associated with hypokalaemia in the exposed group. Older age, female sex, high daily glycyrrhizin dosage, longer duration of glycyrrhizin intake, and potassium-lowering medications were not associated with hypokalaemia after the model adjustment. Elevated direct-bilirubin levels and hypoalbuminaemia may predict pseudoaldosteronism caused by glycyrrhizin.

Keywords: chronic hepatitis; glycyrrhetinic acid; glycyrrhizin; hypokalaemia; multidrug resistance-associated protein 2; pseudoaldosteronism.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Area Under Curve
  • Bilirubin / blood
  • Cohort Effect
  • Female
  • Glycyrrhizic Acid / adverse effects
  • Glycyrrhizic Acid / therapeutic use
  • Hepatitis, Chronic / blood
  • Hepatitis, Chronic / complications*
  • Hepatitis, Chronic / drug therapy*
  • Humans
  • Hypokalemia / blood
  • Hypokalemia / chemically induced
  • Liddle Syndrome / blood
  • Liddle Syndrome / chemically induced*
  • Liddle Syndrome / complications*
  • Male
  • Middle Aged
  • Retrospective Studies
  • Risk Factors
  • Young Adult

Substances

  • Glycyrrhizic Acid
  • Bilirubin